<DOC>
	<DOCNO>NCT02345772</DOCNO>
	<brief_summary>Hormonal therapy fulvestrant 500 mg administer surgery With docetaxel , Trastuzumab , pertuzumab determine pathological complete remission rate time surgery ER-positive HER2-positive patient breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy ( Taxotere , Trastuzumab Pertuzumab ) Patients With HER2-positive ER-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Patients ≥ 18 year age histologically , radiographically confirm nonmetastatic ERpositive ( define ≥30 % positive cell ) HER2positive ( define overexpression immunohistochemistry ( 3+ ) 2+ positive define fluorescence dual situ hybridization . ) breast cancer minimal tumor size 2 cm ( ≥T2 lesion ) receive neoadjuvant chemotherapy recommend treat physician 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status score &lt; 1 3 . Absolute neutrophil count &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 8.5 g/dL 4 . Serum creatinine ≤1.5 time upper limit normal range , total bilirubin ≤ 1.5 X ULN ( ≤ 3 mg/dL clinically diagnose Gilbert syndrome ) AST/ALT ≤ 2.5 X ULN ( AST/ALT ≤ 5X ULN clinically diagnose Gilbert syndrome ) 5 . Women childbearing potential ( i.e. , woman premenoposaul surgically sterile ) must negative serum pregnancy test within 2 week prior begin treatment 1 . Uncontrolled cardiac disease , angina , hypertension significant arrhythmias 2 . LVEF ( leave ventricular ejection fraction ) &lt; 50 % prior assessment . Note : Assessment LVEF do trastuzumabbased chemotherapy standard care 3 . Pregnant lactating female 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement 5 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>